16.01.2013 • News • Lonza • Collaboration

Lonza, BaroFold Announce Technology Evaluation Agreement for PreEMT

Lonza, a leader in biological development and BaroFold, an protein technology developer, announced today a non-exclusive technology and license agreement whereby Lonza will evaluate BaroFold's PreEMT high pressure refolding technology for use in biological development refolding processes. Lonza's evaluation will focus on refolding difficult to express microbial products expressed as inclusion bodies. The PreEMT unit will be installed for evaluation at Lonza's microbial development and manufacturing plant in Visp, Switzerland.

The agreement includes an option for Lonza to extend the platform evaluation to GMP production analysis.

Interview

Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

Innovation Pitch

Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.